JACC-Heart Failure

Papers
(The H4-Index of JACC-Heart Failure is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Wearable Remote Patient Monitoring Devices278
Reply139
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States127
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure122
Developing a System for Best Performance for Cardiac Transplantation121
Reply109
Reply108
Editorial Board106
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure97
Opportunities for Change in Home Health Care in Heart Failure96
Recognizing the Top Reviewers and Top Authors of JACC: Heart Failure96
Correction91
Clinical Implications of the P.V142I TTR Variant85
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction84
Revisiting ICD Therapy for Primary Prevention82
Full issue PDF81
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction81
Curing Ourselves of Toxic Positivity for Hospital-at-Home79
Long-Term Effects of Sotatercept on Right Ventricular Function76
Pulmonary Artery Catheter Timing and Outcomes for Patients With Cardiogenic Shock75
Are Most HFpEF “Phenotypes” Just Different Stages of the Same Disease?74
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies73
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function71
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans67
Delivering Quadruple Therapy for Heart Failure With Reduced Ejection Fraction in a Customizable Polypill66
Contemporary Trends in Heart Failure Mortality65
From Loop Diuretics to Closed-Loop Decongestion65
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype64
Predictors of Incident Heart Failure Diagnosis Setting64
Eating to Prevent Both Heart and Planetary Failure63
Withdrawal of Guideline-Directed Medical Therapy in Heart Failure With Improved Ejection Fraction62
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status59
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia57
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death57
Unique Proteomic Signatures in Human Anthracycline-Induced Dilated Cardiomyopathy55
Associations Between Urinary Metal Levels and Incident Heart Failure53
Inhibiting Both Neprilysin and Phosphodiesterase Type 952
Challenges Addressing Prognosis in Advanced Heart Failure52
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design50
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation48
Plasma Aldosterone Measurement to Guide Prevention and Treatment of Heart Failure in Black Adults With Hypertension48
NT-proBNP48
Peripheral Venous Pressure Measured With a Novel Miniature Transducer in Heart Failure Patients48
Reply47
Prognosis for Acute Myocarditis47
Eplerenone for Nonobstructive Hypertrophic Cardiomyopathy47
High NT-proBNP in Heart Failure47
Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure47
1.4744699001312